Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial
Suzanne Carreira(Institute of Cancer Research), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Jane Goodall, Pasquale Rescigno(Institute of Cancer Research), Wei Yuan(Shanghai Public Health Clinical Center), Bora Gürel(Institute of Cancer Research), Rita Pereira(Institute of Cancer Research), Joaquı́n Mateo(Royal Marsden NHS Foundation Trust), Mateus Crespo(Institute of Cancer Research), Jan Rekowski(Institute of Cancer Research), Emma Hall(Institute of Cancer Research), Susana Miranda(Royal Marsden NHS Foundation Trust), Ruth Riisnaes(Institute of Cancer Research), Alba Llop‐Guevara(Vall d'Hebron Institut de Recerca), Chloe Baker(Institute of Cancer Research), Violeta Serra(Vall d'Hebron Institute of Oncology), Núria Porta, Ana Ferreira(Institute of Cancer Research), Daniel Nava Rodrigues(Institute of Cancer Research), Sara Arce‐Gallego(Hebron University), Stephen J. Pettitt(Gene Therapy Laboratory), Christopher J. Lord(Institute of Cancer Research), Diletta Bianchini(Royal Marsden NHS Foundation Trust), Alec Paschalis(Royal Marsden NHS Foundation Trust), Cláudia Bertan(Institute of Cancer Research), Ines Figueiredo(Institute of Cancer Research), George Seed(Institute of Cancer Research)
Cited by 161
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k